Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

The protective effect of CXC chemokine receptor 2 antagonist on experimental bronchopulmonary dysplasia induced by postnatal systemic inflammation

  • Lee, Seung Hyun (Department of Pediatrics, Wonkwang University College of Medicine) ;
  • Choi, Chang Won (Department of Pediatrics, Seoul National University Bundang Hospital)
  • 투고 : 2020.03.18
  • 심사 : 2020.06.26
  • 발행 : 2021.01.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Animal studies have shown that a leukocyte influx precedes the development of bronchopulmonary dysplasia (BPD) in premature sheep. The CXC chemokine receptor 2 (CXCR2) pathway has been implicated in the pathogenesis of BPD because of the predominance of CXCR2 ligands in tracheal aspirates of preterm infants who later developed BPD. Purpose: To test the effect of CXCR2 antagonist on postnatal systemic and pulmonary inflammation and alveolarization in a newborn Sprague-Dawley rat model of BPD. Methods: Lipopolysaccharide (LPS) was injected intraperitoneally (i.p.) into the newborn rats on postnatal day 1 (P1), P3, and P5 to induce systemic inflammation and inhibit alveolarization. In the same time with LPS administration, CXCR2 antagonist (SB-265610) or vehicle was injected i.p. to investigate whether CXCR2 antagonist can alleviate the detrimental effect of LPS on alveolarization by attenuating inflammation. On P7 and P14, bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) were collected from the pups. To assess alveolarization, mean cord length and alveolar surface area were measured on 4 random nonoverlapping fields per animal in 2 distal lung sections at ×100 magnification. Results: Early postnatal LPS administration significantly increased neutrophil counts in BALF and PB and inhibited alveolarization, which was indicated by a greater mean cord length and lesser alveolar surface area. CXCR2 antagonist significantly attenuated the increase of neutrophil counts in BALF and PB and restored alveolarization as indicated by a decreased mean cord length and increased alveolar surface area in rat pups exposed to early postnatal systemic LPS. Conclusion: CXCR2 antagonist preserved alveolarization by alleviating pulmonary and systemic inflammation induced by early postnatal systemic LPS administration. These results suggest that CXCR2 antagonist can be considered a potential therapeutic agent for BPD that results from disrupted alveolarization induced by inflammation.

키워드

과제정보

This study was supported by the Seoul National University Bundang Hospital Research Fund (grant no. 02-2015-016).

참고문헌

  1. Thebaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019;5:78. https://doi.org/10.1038/s41572-019-0127-7
  2. Isayama T, Lee SK, Mori R, Kusuda S, Fujimura M, Ye XY, et al. Comparison of mortality and morbidity of very low birth weight infants between Canada and Japan. Pediatrics 2012;130:e957-65. https://doi.org/10.1542/peds.2012-0336
  3. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015;314:1039-51. https://doi.org/10.1001/jama.2015.10244
  4. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res 1999;46:641-3. https://doi.org/10.1203/00006450-199912000-00007
  5. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998;29:710-7. https://doi.org/10.1016/S0046-8177(98)90280-5
  6. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006;11:354-62. https://doi.org/10.1016/j.siny.2006.03.004
  7. Wright CJ, Kirpalani H. Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies? Pediatrics 2011;128:111-26. https://doi.org/10.1542/peds.2010-3875
  8. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998;53:81-94. https://doi.org/10.1016/S0378-3782(98)00045-0
  9. Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM, et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:873-7. https://doi.org/10.1016/S0022-5223(19)36903-X
  10. Konrad FM, Reutershan J. CXCR2 in acute lung injury. Mediators Inflamm 2012;2012:740987. https://doi.org/10.1155/2012/740987
  11. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:343-61. https://doi.org/10.2174/1568008043339712
  12. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991;253:1278-80. https://doi.org/10.1126/science.1840701
  13. Belperio JA, Keane MP, Burdick MD, Londhe V, Xue YY, Li K, et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest 2002;110:1703-16. https://doi.org/10.1172/JCI15849
  14. Morgan SJ, Moore MW, Cacalano G, Ley K. Reduced leukocyte adhesion response and absence of slow leukocyte rolling in interleukin-8 receptor-deficient mice. Microvasc Res 1997;54:188-91. https://doi.org/10.1006/mvre.1997.2029
  15. Cacalano G, Lee J, Kikly K, Ryan AM, Pitts-Meek S, Hultgren B, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994;265:682-4. https://doi.org/10.1126/science.8036519
  16. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-8. https://doi.org/10.1074/jbc.273.17.10095
  17. Kotecha S. Cytokines in chronic lung disease of prematurity. Eur J Pediatr 1996;155 Suppl 2:S14-7. https://doi.org/10.1007/BF01958074
  18. Inwald DP, Costeloe K, Murch SH. High concentrations of GRO-alpha and MCP-1 in bronchoalveolar fluid of infants with respiratory distress syndrome after surfactant. Arch Dis Child Fetal Neonatal Ed 1998;78:F234-5. https://doi.org/10.1136/fn.78.3.F234b
  19. Choi CW, Lee J, Oh JY, Lee SH, Lee HJ, Kim BI. Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats. Pediatr Res 2016;79:287-94. https://doi.org/10.1038/pr.2015.224
  20. Schittny JC, Burri PH. Development and growth of the lung. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman's pulmonary diseases and disorders. 4th ed. New York: McGraw-Hill, 2008:91-114.
  21. Bhandari V. Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014;100:189-201. https://doi.org/10.1002/bdra.23220
  22. Strieter RM, Kunkel SL, Keane MP, Standiford TJ. Chemokines in lung injury: Thomas A. Neff Lecture. Chest 1999;116(1 Suppl):103S-110S. https://doi.org/10.1378/chest.116.suppl_1.103S
  23. Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther 2001;299:90-5.
  24. Schittny JC, Burri PH. Development and growth of the lung. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman's pulmonary diseases and disorders. 4th ed. New York: McGraw-Hill, 2008:91-114.
  25. Kallapur SG, Jobe AH, Ball MK, Nitsos I, Moss TJ, Hillman NH, et al. Pulmonary and systemic endotoxin tolerance in preterm fetal sheep exposed to chorioamnionitis. J Immunol 2007;179:8491-9. https://doi.org/10.4049/jimmunol.179.12.8491
  26. Jobe AH, Newnham JP, Willet KE, Moss TJ, Gore Ervin M, Padbury JF, et al. Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. Am J Respir Crit Care Med 2000;162:1656-61. https://doi.org/10.1164/ajrccm.162.5.2003044
  27. Hogmalm A, Backstrom E, Bry M, Lappalainen U, Lukkarinen HP, Bry K, Role of CXC chemokine receptor-2 in a murine model of bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2012;47:746-58. https://doi.org/10.1165/rcmb.2011-0394OC
  28. Lin G, Pearson AE, Scamurra RW, Zhou Y, Baarsch MJ, Weiss DJ, et al. Regulation of interleukin-8 expression in porcine alveolar macrophages by bacterial lipopolysaccharide. J Biol Chem 1994;269:77-85. https://doi.org/10.1016/S0021-9258(17)42316-7
  29. Xu WB, Haddad EB, Tsukagoshi H, Adcock I, Barnes PJ, Chung KF. Induction of macrophage inflammatory protein 2 gene expression by interleukin 1 beta in rat lung. Thorax 1995;50:1136-40. https://doi.org/10.1136/thx.50.11.1136
  30. Ahuja SK, Lee JC, Murphy PM. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem 1996;271:225-32. https://doi.org/10.1074/jbc.271.1.225
  31. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001;344:95-101. https://doi.org/10.1056/NEJM200101113440203
  32. O'Reilly M, Thebaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol 2014;307:L948-58. https://doi.org/10.1152/ajplung.00160.2014
  33. Choi CW, Kim BI, Hong JS, Kim EK, Kim HS, Choi JH. Bronchopulmonary dysplasia in a rat model induced by intra-amniotic inflammation and postnatal hyperoxia: morphometric aspects. Pediatr Res 2009;65:323-7. https://doi.org/10.1203/PDR.0b013e318193f165
  34. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;164:1971-80. https://doi.org/10.1164/ajrccm.164.10.2101140